Figure 4
Figure 4. Individual change in SPD from baseline in the 300-mg (A), 500-mg (B), 700-mg (C), and 1000-mg (D) dose groups. Two patients in the 300-mg group (A) were without indicator lesions; hence, data from 8 patients only are presented. One patient in the 500-mg group (B) was withdrawn at visit 2; hence, data from 9 patients only are presented. Bold lines represent clinical responders. One patient in the 1000-mg group (D) showed less than 50% reduction in the SPD at week 11 and 19 but was considered as a nonresponder as a confirmational lymph node biopsy was positive.

Individual change in SPD from baseline in the 300-mg (A), 500-mg (B), 700-mg (C), and 1000-mg (D) dose groups. Two patients in the 300-mg group (A) were without indicator lesions; hence, data from 8 patients only are presented. One patient in the 500-mg group (B) was withdrawn at visit 2; hence, data from 9 patients only are presented. Bold lines represent clinical responders. One patient in the 1000-mg group (D) showed less than 50% reduction in the SPD at week 11 and 19 but was considered as a nonresponder as a confirmational lymph node biopsy was positive.

Close Modal

or Create an Account

Close Modal
Close Modal